In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $67.21, marking a +1.04% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Stephen Tsang, MD, PhD, professor at Columbia University and attending physician at NewYork-Presbyterian Hospital, shared encouraging early findings on the use of optogenetic therapy for patients with ...

St. Jude researchers advance CASTs, enhancing precision and activity for next-generation genome-editing therapies.

Classical swine fever reduces productivity and harms animal welfare, but pigs have now been genetically edited to make them ...

Three copies of chromosome 21 cause Down syndrome (DS), and roughly half of children born each year in the United States with ...

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

When six infants around the world were diagnosed with an odd trio of symptoms (diabetes, epilepsy, and abnormally small heads ...

Voss and his team have used CRISPR gene-editing to reprogram human B cells to produce antibodies that can recognize and block many different strains of HIV. And although existing humanized mouse ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...

Despite the mechanisms that made it a “biologically plausible” candidate, the study found that participants who took the drug ...

LinkedIn co-founder Reid Hoffman warns that Silicon Valley's software obsession is limiting AI opportunities in healthcare ...